NICE gives final green light for Amgen's Nplate
This article was originally published in Scrip
Executive Summary
NICE, the heath technology appraisal body for England and Wales, has today published final guidance recommending Amgen's thrombopoietin receptor agonist Nplate (romiplostim) for some patients with chronic idiopathic thrombocytopenic purpura (ITP).